文献速递腹部介入CTMR

经动脉化疗栓塞治疗的单发小肝癌患者的影像学生存预测因素

Imaging Predictors of Survival in Patients with Single Small Hepatocellular Carcinoma Treated with Transarterial Chemoembolization.
PubMed 文献 · Korean J Radiol · 2020-08-28

这项回顾性研究纳入2004至2014年间接受经动脉化疗栓塞作为一线治疗的750例肝功能储备良好、单发小肝癌患者,随机分为训练集525例和验证集225例。多因素Cox分析选出3项治疗前影像学表现(肿瘤边缘、肿瘤位置、强化方式)和2项临床因素(年龄、血清白蛋白水平)构建预测模型;验证集低、中、高危组中位总生存期分别为137.5、76.1和44.0个月(p<0.001)。治疗前CT或MR影像表现可预测接受经动脉化疗栓塞的小肝癌患者生存结局,所建模型可能有助于预后判断和筛选适合经动脉化疗栓塞的候选者。

要点

  • 治疗前肿瘤边缘、肿瘤位置和强化方式是单发小肝癌经动脉化疗栓塞后生存的独立影像预测因素。
  • 联合年龄和血清白蛋白水平构建的模型可将患者分为低、中、高危组,验证集中位总生存期分别为137.5、76.1和44.0个月。
  • 模型对总生存和局部肿瘤无进展生存的验证集3年、5年、10年AUC分别为0.734/0.802/0.775和0.738/0.789/0.791。

核心结论

  • 治疗前CT或MR影像表现可预测接受经动脉化疗栓塞的单发小肝癌患者的生存结局,包含3项影像预测因素的模型可能有助于预后判断和筛选适合经动脉化疗栓塞的候选者。

研究设计与样本

  • 回顾性研究,纳入2004至2014年间接受经动脉化疗栓塞作为一线治疗的750例肝功能储备良好、单发小肝癌患者,随机分为训练集525例和验证集225例;以治疗前CT或MR影像表现及临床因素构建预测模型。

关键影像表现/征象

  • 治疗前影像学表现中肿瘤边缘、肿瘤位置和强化方式被选入预测模型。
  • 训练集多因素Cox分析选出3项影像学表现和2项临床因素(年龄、血清白蛋白水平)并计分建模。

诊断标准与关键数值

  • 验证集低、中、高危组中位总生存期分别为137.5个月、76.1个月和44.0个月(p<0.001)。
  • 验证集总生存预测模型3年、5年、10年时间依赖ROC曲线AUC分别为0.734、0.802和0.775。
  • 验证集局部肿瘤无进展生存预测模型3年、5年、10年AUC分别为0.738、0.789和0.791。
  • 验证集无进展生存预测模型3年、5年、10年AUC分别为0.671、0.733和0.694。

临床应用与阅片要点

  • 作者认为包含3项影像预测因素的模型可能有助于预后判断、识别和筛选适合经动脉化疗栓塞的单发小肝癌患者。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVE: Clinical outcomes of patients who undergo transarterial chemoembolization (TACE) for single small hepatocellular carcinoma (HCC) are not consistent, and may differ based on certain imaging findings. This retrospective study was aimed at determining the efficacy of pre-TACE CT or MR imaging findings in predicting survival outcomes in patients with small HCC upon being treated with TACE. Besides, the study proposed to build a risk prediction model for these patients.

MATERIALS AND METHODS: Altogether, 750 patients with functionally good hepatic reserve who received TACE as the first-line treatment for single small HCC between 2004 and 2014 were included in the study. These patients were randomly assigned into training (n = 525) and validation (n = 225) sets.

RESULTS: According to the results of a multivariable Cox analysis, three pre-TACE imaging findings (tumor margin, tumor location, enhancement pattern) and two clinical factors (age, serum albumin level) were selected and scored to create predictive models for overall, local tumor progression (LTP)-free, and progression-free survival in the training set. The median overall survival time in the validation set were 137.5 months, 76.1 months, and 44.0 months for low-, intermediate-, and high-risk groups, respectively (p < 0.001). Time-dependent receiver operating characteristic curves of the predictive models for overall, LTP-free, and progression-free survival applied to the validation cohort showed acceptable areas under the curve values (0.734, 0.802, and 0.775 for overall survival; 0.738, 0.789, and 0.791 for LTP-free survival; and 0.671, 0.733, and 0.694 for progression-free survival at 3, 5, and 10 years, respectively).

CONCLUSION: Pre-TACE CT or MR imaging findings could predict survival outcomes in patients with small HCC upon treatment with TACE. Our predictive models including three imaging predictors could be helpful in prognostication, identification, and selection of suitable candidates for TACE in patients with single small HCC.

来源:Korean J Radiol,查看原文。版权归原作者所有。

引用

  1. Park C, Kim JH, Kim PH, et al. Imaging Predictors of Survival in Patients with Single Small Hepatocellular Carcinoma Treated with Transarterial Chemoembolization. Korean J Radiol. 2020. PMID: 32901464. doi:10.3348/kjr.2020.0325

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。